KMDA Kamada Ltd.

+0.03  (1%)
Previous Close 4.78
Open 4.80
Price To book 2.82
Market Cap 193222752
Shares 40,254,740
Volume 92,774
Short Ratio 1.91
Av. Daily Volume 130,357

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated April 2016
Alpha-1 antitrypsin (AAT)
Prevention of lung transplant rejection
Approval announced August 25, 2017.
Prophylaxis of rabies disease
Top-line data released August 30, 2016. Primary endpoint met. Pivotal trial planned for 2018.
Inhaled formulation of AAT
AATD - Alpha-1 Antitrypsin deficiency
Phase 2/3 data due 2H 2017.
Alpha-1 Antitrypsin (AAT)
Pediatric patients newly diagnosed with type 1 diabetes
Phase 2/3 trial to be initiated 2018.
Alpha-1 antitrypsin (AAT)
Graft Versus Host Disease (GvHD)

Latest News

  1. Kamada Announces CFO Transition
  2. ETFs with exposure to Kamada Ltd. : September 14, 2017
  3. Kamada Ltd. :KMDA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
  4. Kamada to Present Corporate Overview at Two Investor Conferences in September
  5. Kamada Announces Collaboration with BGN Technologies for Advanced Alpha-1 Antitrypsin Research with a Focus on Mechanism of Action
  6. Kamada Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
  7. Kamada (KMDA) Gets FDA Approval for Rabies Vaccine
  8. Featured Company News - FDA Approves Kedrion Biopharma and Kamada's KEDRAB(TM) for Post-Exposure Prevention of Rabies Infection
  9. Kedrion Biopharma and Kamada Receive FDA Approval of KEDRAB™ for Post-Exposure Prophylaxis Against Rabies Infection
  10. Kamada posts 2Q profit
  11. Kamada Reports Financial Results for Second Quarter and First Six Months of 2017
  12. Kamada Announces Pricing of Public Offering of Ordinary Shares
  13. Kamada Pre-Announces Certain Preliminary Financial Results for Second Quarter and First Six Months of 2017
  14. Kamada Announces Proposed Public Offering of Ordinary Shares
  15. Kamada to Host Second Quarter 2017 Financial Results Conference Call on August 1
  16. ETFs with exposure to Kamada Ltd. : July 7, 2017
  17. Kamada Withdraws Inhaled AAT Marketing Application in EU